Calcium channel blockers and Alzheimer's disease: potential relevance in treatment strategies of metabolic syndrome.

@article{Goodison2012CalciumCB,
  title={Calcium channel blockers and Alzheimer's disease: potential relevance in treatment strategies of metabolic syndrome.},
  author={William V Goodison and V. Frisardi and P. Kehoe},
  journal={Journal of Alzheimer's disease : JAD},
  year={2012},
  volume={30 Suppl 2},
  pages={
          S269-82
        }
}
  • William V Goodison, V. Frisardi, P. Kehoe
  • Published 2012
  • Medicine
  • Journal of Alzheimer's disease : JAD
  • Midlife hypertension is a risk factor for late onset Alzheimer's disease (AD) and it is one of the components of metabolic syndrome (MetS). Observational studies and some cardiovascular disease-related clinical trials suggest that antihypertensive treatment reduced the incidence and progression of AD. Calcium channel blockers (CCBs), one of the more commonly used treatments for hypertension, target voltage-gated calcium channels (VGCCs) which are found on neurons in the brain where calcium… CONTINUE READING
    30 Citations
    Current status of renin–aldosterone angiotensin system-targeting anti-hypertensive drugs as therapeutic options for Alzheimer's disease
    • 44
    Cracking novel shared targets between epilepsy and Alzheimer’s disease: need of the hour
    • 6
    Somatic comorbidities and Alzheimer’s disease treatment
    • 12
    • PDF
    Prevention Trials in Alzheimer's Disease: Current Status and Future Perspectives.
    • 17